Takeda strikes US$640m deal with Enterome
French Enterome SA has added a second licence agreement with Takeda to its deal portfolio, projecting possible payments of US$640m.
EMA recommends four biologicals for market
The European Medicines Agency delays the EU approval of Nivolumab/Ipilimumab in NSCLC and greenlights four biotherapeutics to be marketed in the EU.
Companies at EFIB set to drive the bioeconomy
Industrial biotech innovations, presented in at the 11th EFIB in Toulouse, could become the key enabler set to save our planet if supported appropriately.
Oxford Nanopore wins over Amgen
Oxford Nanopore Technologies has impressed Amgen with its genetic sequencing technology. The US biopharma major has invested £50m in the Oxford-based company.
French Acticor Biotech raises 15.3m
In a Series B financing round, INSERM spin-off Acticor Biotech has raised 15.3m from European and Asian investors. The new financing will go towards the launch off the first Phase II clinical trial of its lead candidate ACT017 in acute ischemic stroke.
HiFiBiO bags immuno-oncology specialist H-Immune
Multinational biotherapeutics company HiFiBiO Therapeutics announced that it has taken over early stage biotech H-Immune Therapeutics. With the acquisition of the French Atomic Energy Commission spin-out, HiFiBiO aims to strengthen its strategic focus on targetting differenct T cell subsets and combat cancer.
Phase III success for Roche breast cancer drug
Roche has announced that in a Phase III trial, its antibody-drug conjugate Kadcyla showed improved invasive disease-free survival in breast cancer patients.
Targovax reports promising disease-free survival (DFS) data
Targovax ASA has reported promising disease-free survival (DFS) data from Tg01 in resected pancreatic cancer.
EU set to speed up switch to bioeconomy by new action plan
Six years after the European Commission created the world’s first bioeconomy strategy and action plan, it presented a new action plan aimed at moving faster towards a climate-neutral, sustainable, biobased industry.
Bacterial antigen mimicry drives MS
T cells target a bacterial variant of a human enzyme promoting autoimmune diseases such as Multiple Sclerosis (MS).